Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cutan Ocul Toxicol ; 37(2): 133-138, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28707522

RESUMEN

PURPOSE: To investigate the effect of Bosentan (non-selective endothelin receptor antagonist) and BQ123 (ETA receptor antagonist) on intraocular inflammation in an endotoxin-induced uveitis (EIU) rabbit model. METHODS: Uveitis was induced by intravitreal injection of lipopolysaccharide (LPS). The animals were divided into 7 groups and there were six rabbits in each group (saline, saline and ethanol, bosentan, BQ123, lipopolysaccharide (LPS), bosentan and LPS, BQ123 and LPS-injected groups). Bosentan and BQ123 were applied before LPS injection. Aqueous humour was collected at 24th hour post-injections and enucleation was performed for the evaluation of histopathological changes. RESULTS: BQ123 decreased clinical score, cell counts and protein amount more than bosentan and it was significant for cell counts (p = 0.018). Bosentan significantly diminished inflammatory reactions more than BQ123 as shown in histopathological specimens (p = 0.002). CONCLUSIONS: ETA receptor blockage is effective on uveitis treatment by its protective effect on blood aqueous barrier.


Asunto(s)
Antagonistas de los Receptores de Endotelina/uso terapéutico , Péptidos Cíclicos/uso terapéutico , Sulfonamidas/uso terapéutico , Uveítis/tratamiento farmacológico , Animales , Humor Acuoso/metabolismo , Bosentán , Modelos Animales de Enfermedad , Antagonistas de los Receptores de Endotelina/farmacología , Ojo/efectos de los fármacos , Ojo/metabolismo , Ojo/patología , Proteínas del Ojo/metabolismo , Inyecciones Intravítreas , Recuento de Leucocitos , Lipopolisacáridos , Masculino , Péptidos Cíclicos/farmacología , Conejos , Sulfonamidas/farmacología , Uveítis/sangre , Uveítis/inducido químicamente , Uveítis/patología
2.
Mediators Inflamm ; 2014: 643525, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25165412

RESUMEN

PURPOSE: We investigated the effect of eritoran, a Toll-like receptor 4 antagonist, on retinochoroidal inflammatory damage in an endotoxin-induced inflammatory rat model. METHODS: Endotoxin-induced inflammatory model was obtained by intraperitoneal injection of 1.5 mg/kg lipopolysaccharide (LPS). Group 1 had control rats; in groups 2-3 LPS and 0.5 mg/kg sterile saline were injected; and in groups 4-5 LPS and 0.5 mg/kg eritoran were injected. Blood samples were taken and eyes were enucleated after 12 hours (h) (groups 2 and 4) or 24 hours (Groups 3 and 5). Tumor necrosis factor-α (TNF-α) and malondialdehyde (MDA) levels in the serum and retinochoroidal tissue and nuclear factor kappa-B (NFκB) levels in retinochoroidal tissue were determined. Histopathological examination was performed and retinochoroidal changes were scored. RESULTS: Eritoran treatment resulted in lower levels of TNF-α, MDA, and NFκB after 12 h which became significant after 24 h. Serum TNF-α and retinochoroidal tissue NFκB levels were similar to control animals at the 24th h of the study. Eritoran significantly reversed histopathological damage after 24 h. CONCLUSIONS: Eritoran treatment resulted in less inflammatory damage in terms of serum and retinochoroidal tissue parameters.


Asunto(s)
Disacáridos/uso terapéutico , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Lipopolisacáridos/toxicidad , Fosfatos de Azúcar/uso terapéutico , Receptor Toll-Like 4/antagonistas & inhibidores , Animales , Inflamación/metabolismo , Masculino , Malondialdehído/sangre , Malondialdehído/metabolismo , FN-kappa B/sangre , FN-kappa B/metabolismo , Ratas , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/metabolismo
3.
J Ocul Pharmacol Ther ; 27(6): 545-52, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21848425

RESUMEN

PURPOSE: This study aimed to investigate the effects of anandamide or arachidonylethanolamide (AEA), an endogenous cannabinoid receptor agonist, on intraocular inflammation in an endotoxin-induced uveitis (EIU) model in rabbits. METHODS: Forty New Zealand albino male rabbits were used (5 groups, 8 animals in each). After establishment of sufficient anesthesia, animals were taken under surgery for intravitreal injections. A maximum amount of 50 µL of solution was injected into the central vitreous with a 30-gauge needle. In the control group, sterile saline was injected into the right eyes of the animals. Likewise, AEA (10(-5) M) in the second group, lipopolysaccharide (LPS; 100 ng) in the third group, and AEA (10(-5) M) and LPS (100 ng) in the fourth group were administered. Fifth group received 0.1 mL subtenon injection of AM251 (10(-5) M), a CB(1)-receptor antagonist, 30 min prior to intravitreal LPS (100 ng) and AEA (10(-5) M) injection. At 24 h after the surgical intervention, clinical evaluation was performed and animals were then euthanized with 100 mg/kg intravenous pentobarbital injections. Immediately after the induction of pentobarbital anesthesia, the anterior chamber of the eyes was quickly punctured using a 30-gauge needle to drain aqueous humor (AH) and obtained specimens were used for cell count, protein measurement, and microbiological contamination tests. After AH collection, enucleation was performed and enucleated material was kept for the pathological evaluation. RESULTS: AEA caused an overall worsening of EIU in studied eyes. It significantly increased the detrimental effects of endotoxin, as assessed by clinical investigation of ocular inflammation, AH leukocyte content, and AH protein concentrations. CB(1)-receptor antagonist AM251 administration reversed some components of this AEA-induced exacerbation to significant extents. CONCLUSION: AEA exacerbated EIU in rabbit eyes. AM251 has been found beneficial to prevent AEA's aggravating impact on EIU. As AEA is a treatment choice for lowering intraocular pressure in ophthalmology practice, concurrent use of CB(1)-receptor antagonists may be a questionable strategy in cases of secondary glaucoma, to avoid aggravation of the present inflammation.


Asunto(s)
Ácidos Araquidónicos/farmacología , Lipopolisacáridos/toxicidad , Alcamidas Poliinsaturadas/farmacología , Uveítis/inducido químicamente , Animales , Agonistas de Receptores de Cannabinoides , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Endocannabinoides , Inyecciones Intravítreas , Recuento de Leucocitos , Masculino , Infiltración Neutrófila/efectos de los fármacos , Piperidinas/farmacología , Pirazoles/farmacología , Conejos , Receptor Cannabinoide CB1/antagonistas & inhibidores , Índice de Severidad de la Enfermedad , Uveítis/inmunología , Uveítis/patología
4.
Arch Med Res ; 38(5): 503-11, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17560455

RESUMEN

BACKGROUND: Because hyperglycemia-induced oxidative stress may be a cause of retinopathy, this study examined the hypothesis that administration of exogenous antioxidants, stobadine (ST) and vitamin E (vitE), can restore retinal abnormalities in experimental diabetes. METHODS: Normal and streptozotocin (STZ)-induced male Wistar rats received daily intraoral doses of ST (24.7 mg/kg) and vitE (alpha-dl-tocopherol acetate, 400-500 IU/kg) individually or in combinations for 8 months. The biochemical parameters including aldose reductase enzyme (AR) activity and lipid peroxidation (MDA), and histopathological changes such as retinal capillary basement membrane thickness (RCBMT) and vascular endothelial growth factor (VEGF) expression were evaluated. RESULTS: A 37.99% increase in RCBMT was observed in rats after 8 months diabetes duration. The increase in RCBMT was 12.34% in diabetic rats treated with ST and 23.07% in diabetic rats treated with vitE. In diabetic rats treated with antioxidant combination, just a 4.38% increase was observed in RCBMT. The excess VEGF immunoreactivity and increased MDA and AR activity determined in diabetic retina were significantly attenuated by individual antioxidant treatments. Although both antioxidants decreased blood glucose, HbA1c, fructosamine and triglyceride levels in diabetic rats, poor glycemic control was maintained in all experimental groups during the treatment period. However, the antioxidant combination led to almost complete amelioration in retinal MDA and RCBMT in diabetic rats. CONCLUSIONS: The ability of antioxidant combination to arrest retinal abnormalities and lipid peroxidation even in the presence of poor glycemic control might advocate the key role of direct oxidative damage and the protective action of antioxidants in retinal alterations associated with diabetic retinopathy.


Asunto(s)
Antioxidantes/farmacología , Carbolinas/farmacología , Retinopatía Diabética/metabolismo , Estrés Oxidativo , Vitamina E/farmacología , Aldehído Reductasa/metabolismo , Animales , Antioxidantes/uso terapéutico , Glucemia , Carbolinas/administración & dosificación , Carbolinas/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/metabolismo , Retinopatía Diabética/sangre , Retinopatía Diabética/tratamiento farmacológico , Factores de Crecimiento Endotelial/metabolismo , Inmunohistoquímica , Masculino , Malondialdehído/metabolismo , Ratas , Ratas Wistar , Retina/química , Retina/enzimología , Retina/patología , Vitamina E/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA